The Reflux Company
The Reflux Company is a medical technology firm that markets a portfolio of FDA-cleared diagnostic and therapeutic devices for GERD and LPR, serving ENT specialists, gastroenterologists, and reflux patients across the full continuum from at-home testing to minimally invasive treatment.
- Company typePrivate
- Founded2025
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What The Reflux Company does
The Reflux Company is a privately held medical technology firm founded in 2025 by Thomas Ball, Ph.D., that has assembled a portfolio of FDA-cleared devices covering the full reflux care continuum, from diagnosis through treatment, for both Gastroesophageal Reflux Disease (GERD) and Laryngopharyngeal Reflux (LPR). The portfolio comprises four distinct products: the Restech Dx-pH System, a 24-hour ambulatory pH monitoring probe that is the only sensor able to monitor continuous pH in both liquid and aerosolized states in the upper airway; PepsinCheck by Peptest, an at-home saliva lateral-flow assay that detects pepsin as biological evidence of reflux reaching the throat; Stretta Therapy, a minimally invasive endoscopic radiofrequency procedure that strengthens the lower esophageal sphincter without implants or incisions; and the Reflux Band, an external wearable device worn during sleep that applies targeted pressure to the cricoid cartilage to reduce nighttime reflux. The company sells through a hybrid go-to-market: direct-to-consumer e-commerce for PepsinCheck (priced at $149.99 per kit), tiered clinician bulk ordering for diagnostic kits ($125-$1,100 bundles), and enterprise sales of procedure-based products such as Stretta to gastroenterologists and surgical centers. International expansion is supported by the MAAB Group, which acts as an advisory and distribution partner for Asian markets with a focus on China, while manufacturing of the Stretta device is handled by Nissha Medical Technologies under a 2026 partnership. Founded on the thesis that reflux care is fragmented, the company positions itself as the only global firm devoted exclusively to reflux diagnosis and treatment, targeting both clinicians (ENT specialists, gastroenterologists) and reflux patients directly.
The Reflux Company firmographics
Firmographics- Name
- The Reflux Company
- Legal name
- The Reflux Company
- Website
- https://refluxcompany.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- The Reflux Company is a medical technology firm that markets a portfolio of FDA-cleared diagnostic and therapeutic devices for GERD and LPR, serving ENT specialists, gastroenterologists, and reflux patients across the full continuum from at-home testing to minimally invasive treatment.
- Ownership category
- akta.pro rank
The Reflux Company industry classification
Industry- Product category
- Reflux Diagnostic and Therapeutic Medical Devices
- NAICS
- Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- General Gastroenterology (HLAKAEAA)
Keywords
Where The Reflux Company is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
The Reflux Company business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain
Revenue model
- Diagnostic Product Sales: Direct-to-consumer and clinician sales of diagnostic kits including PepsinCheck home test kits and clinician bulk ordering. Revenue from saliva collection test kits sold at various tier levels.
- Stretta Procedure: Minimally invasive outpatient procedure revenue from gastroenterologists and surgical centers. Scheduled for January 2027 relaunch.
- Dx-pH Testing Services: Diagnostic pH monitoring services and equipment for ENT specialists and gastroenterologists to detect laryngopharyngeal reflux.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | PepsinCheck Direct-to-Consumer Kit |
| Unit Pricing | Pay-as-you-go | Clinician Single Kit |
| Unit Pricing | Pay-as-you-go | Clinician Five Kit Bundle |
| Unit Pricing | Pay-as-you-go | Clinician Ten Kit Bundle |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels3 records
The Reflux Company product offering
Product offeringCore offering
The Reflux Company develops and commercializes a portfolio of FDA-cleared medical devices for diagnosing and treating Gastroesophageal Reflux Disease (GERD) and Laryngopharyngeal Reflux (LPR). The portfolio includes the Restech Dx-pH System for upper airway pH monitoring, Stretta Therapy (a minimally invasive endoscopic radiofrequency procedure for chronic GERD), the Reflux Band (a wearable nighttime device), and PepsinCheck by Peptest (an at-home saliva-based diagnostic kit). Products are sold direct-to-consumers via web store and to clinicians, ENTs, gastroenterologists, and healthcare facilities.
Product overview
The Reflux Company offers a unified platform of FDA-cleared medical devices spanning the full spectrum of reflux diagnosis and treatment. The portfolio includes: the Restech Dx-pH System as a diagnostic tool that measures pH in the upper airway (the only sensor that monitors both liquid and aerosolized reflux); Stretta Therapy as a minimally invasive therapeutic procedure using radiofrequency energy for chronic GERD; the Reflux Band as a wearable external device worn during sleep to reduce nighttime reflux; and PepsinCheck by Peptest as an at-home saliva test kit for detecting pepsin. Together, these products provide a comprehensive patient-centered solution from identifying reflux through treatment, designed to work together under one platform.
Differentiator
Problem solved
Functional benefit
Brands
- Restech Dx-pH: A 24-hour pH test that detects changes in pH in the upper airway. The first and only medical sensor able to monitor real-time, continuous pH in both liquid and aerosolized states.
- Stretta
- Reflux Band
- PepsinCheck by Peptest
Products and services
- Restech Dx-pH System A 24-hour ambulatory pH monitoring system that measures pH in the upper airway to detect laryngopharyngeal reflux (LPR). Uses a thin flexible probe placed through the nose with sensor in the throat, connected to a small recorder worn for 24 hours. It is the only sensor able to monitor real-time continuous pH in both liquid and aerosolized states. Designed for ENT specialists and clinicians diagnosing patients with unexplained upper airway symptoms.
- Stretta Therapy A minimally invasive, endoscopic procedure using controlled radiofrequency (RF) energy to strengthen tissue of the lower esophageal sphincter (LES), reducing reflux that causes chronic GERD symptoms. Requires no incisions, no implants, and no overnight hospital stay. Over 35,000 procedures have been performed worldwide and evaluated in more than 40 clinical studies. Targeted at gastroenterologists and surgical centers treating chronic GERD patients seeking alternatives to long-term medication or invasive surgery.
- Reflux Band An external wearable device worn around the neck during sleep that applies gentle targeted pressure to the cricoid cartilage to support the upper esophageal sphincter (UES), reducing nighttime reflux from reaching the upper airway. Adjustable, portable, and designed for easy nightly use. Targeted at consumers and patients seeking non-invasive nighttime reflux symptom management.
- PepsinCheck by Peptest A simple saliva test for detecting pepsin (a digestive enzyme produced exclusively in the stomach) to provide biological evidence of reflux reaching the throat and airway. Saliva is collected at home, shipped back in prepaid packaging, and analyzed in a certified laboratory using lateral flow technology. No probes, no sedation, no clinic visit, and no prescription required. Available direct-to-consumer at $149.99 per kit and to clinicians in bulk at tiered pricing.
Quantifiable outcome
- Over 35,000 Stretta procedures performed worldwide
- +3 more outcomes
Companies that use The Reflux Company
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles4 records
The Reflux Company technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
The Reflux Company partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Nissha Medical TechnologiescoreManufacturing partnership with Nissha Medical Technologies in support of Stretta procedure relaunch. Nissha is a global leader in design and contract manufacturing of single-use medical devices with particular expertise in minimally invasive surgical instruments. Headquartered in Buffalo, New York with worldwide production and innovation centers. Relaunch scheduled for January 2027.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
The Reflux Company competitors and assessment
Company assessmentDirect peers
- Diversatek Healthcare: Specializes in esophageal diagnostics including high-resolution manometry and pH/impedance monitoring systems used by gastroenterologists—directly competing with the Dx-pH System in the clinical reflux-diagnostic channel.
- Respiratory Technology Corporation (Restech): Original developer of the Restech Dx-pH technology that The Reflux Company commercializes; operates in the same upper-airway reflux diagnostic category with overlapping ENT and GI customers.
- Laborie Medical Technologies: Provider of GI diagnostic and urodynamic equipment, including esophageal manometry and pH monitoring products that overlap with The Reflux Company's diagnostic portfolio in gastroenterology clinics.
- Phathom Pharmaceuticals: GI-focused specialty pharmaceutical company commercializing vonoprazan for erosive GERD and H. pylori—represents the pharmaceutical alternative path for reflux treatment against which Stretta must compete for physician adoption.
- EndoGastric Solutions: Developer of the EsophyX device for Transoral Incisionless Fundoplication (TIF), a direct minimally invasive GERD procedure competitor to Stretta. Operates in the same gastroenterology channel with overlapping patient populations.
- Torax Medical (Ethicon, Johnson & Johnson): Acquired by J&J's Ethicon, Torax commercializes the LINX Reflux Management System—a magnetic sphincter augmentation device that directly competes with Stretta for chronic GERD patients seeking alternatives to long-term PPI use.
Broad incumbents
- Medtronic: Large diversified medtech with an extensive GI portfolio including legacy diagnostics, surgical solutions, and the LINX system (via prior acquisition pathway). Represents the deep-pocketed incumbent competitor in the broader reflux and GI space.
- Olympus Medical: Global leader in GI endoscopy equipment and a dominant incumbent in gastroenterology procedural suites where Stretta is performed—representing both a potential channel partner and a competitor for capital budgets.
- Pentax Medical (HOYA Corporation): Major manufacturer of GI endoscopy and diagnostic imaging systems used by gastroenterologists; competes for procedure-suite capital expenditure and adjacent diagnostic workflows relevant to The Reflux Company's portfolio.
- Cook Medical: Broad-line medical device manufacturer with a significant GI endoscopy and intervention portfolio, serving many of the same gastroenterologists and surgical centers where Stretta is positioned.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
The Reflux Company social profiles
Digital presenceThe Reflux Company financial estimates
Financial estimateRevenue estimate
Valuation estimate
The Reflux Company leadership team
Management profileNumber of profiles
Profiles5 records
The Reflux Company funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
The Reflux Company M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about The Reflux Company
What does The Reflux Company do?
The Reflux Company develops and commercializes a portfolio of FDA-cleared medical devices for diagnosing and treating Gastroesophageal Reflux Disease (GERD) and Laryngopharyngeal Reflux (LPR). The portfolio includes the Restech Dx-pH System for upper airway pH monitoring, Stretta Therapy (a minimally invasive endoscopic radiofrequency procedure for chronic GERD), the Reflux Band (a wearable nighttime device), and PepsinCheck by Peptest (an at-home saliva-based diagnostic kit). Products are sold direct-to-consumers via web store and to clinicians, ENTs, gastroenterologists, and healthcare facilities.
Is The Reflux Company a public or private company?
The Reflux Company is a private company. It is classified as venture growth investor backed and is currently operating.
When was The Reflux Company founded?
The Reflux Company was founded in 2025. It employs 1 to 10 people.
Where is The Reflux Company based?
The Reflux Company is headquartered in San Diego, United States, in the North America region.
How does The Reflux Company make money?
Three revenue lines are on record. Diagnostic Product Sales are the primary driver. The others are stretta Procedure and dx-pH Testing Services.
Who are The Reflux Company's main competitors?
Direct peers on record are Diversatek Healthcare, Respiratory Technology Corporation (Restech), Laborie Medical Technologies, Phathom Pharmaceuticals, EndoGastric Solutions and Torax Medical (Ethicon, Johnson & Johnson). Broad incumbents are Medtronic, Olympus Medical, Pentax Medical (HOYA Corporation) and Cook Medical.
Does The Reflux Company have an API?
No public API is recorded for The Reflux Company.
What industry is The Reflux Company in?
The Reflux Company's product category is Reflux Diagnostic and Therapeutic Medical Devices. Its primary akta.pro industry code is HLAKAEAA, General Gastroenterology. Its NAICS code is 334516 and its SIC code is 3841.